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Objectives. The aim of the present study was to evaluate the
influence of radiographic contrast media (CM) on alteplase-
induced coronary thrombolysis.
Background. Contrast media inhibit fibrinolysis in vitro and
interact with endothelial cells, platelets and the coagulation
system. The in vivo effects of CM on thrombolysis are not known.
Methods. Occlusive coronary artery thrombosis was induced in
4 groups of 10 dogs by the copper coil technique. After 70 min of
occlusion the dogs were randomized to intracoronary injection of
2 ml kg21 of either saline, a low-osmolar ionic CM (ioxaglate), a
low-osmolar nonionic CM (iohexol) or a high-osmolar ionic CM
(amidotrizoate). Thrombolysis with alteplase and co-therapy with
aspirin and heparin was initiated after 90 min of occlusion. The
coronary artery flow was monitored with an electromagnetic
flowmeter throughout the experiment.
Results. Iohexol and amidotrizoate, but not ioxaglate, were
associated with longer reperfusion delays (time to optimal reper-
fusion: 67 6 48 min and 65 6 49 min, respectively, vs. 21 6 11 min
after placebo; p < 0.05) and shorter periods of coronary perfusion
(optimal perfusion time: 21 6 26 min and 21 6 28 min, respec-
tively, vs. 58 6 40 min after placebo; p < 0.05). No significant
differences were observed between groups with regard to activated
partial thromboplastin times, circulating thrombin-antithrombin
III complex concentrations and fibrinogen.
Conclusions. In this animal model administration of iohexol
and amidotrizoate before thrombolysis significantly delayed
reperfusion. This interaction should be considered in the design of
clinical trials of thrombolytic therapy that evaluate coronary
artery patency and in patients receiving local infusions of fibrino-
lytic agents.
(J Am Coll Cardiol 1998;32:1102–8)
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The interaction between radiographic contrast media (CM)
and hemostasis has been a subject of intense debate during the
last decade. Since Robertson’s first report (1) of clots being
more likely formed in syringes containing nonionic than ionic
CM, numerous studies have addressed the “clotting issue.”
Much has been learned about the interaction of CM with
endothelial cells (2–4), platelets (5–7) and coagulation pro-
teins (8–11). The effect of CM on endogenous fibrinolysis has
also been described (12,13), but little is known about the
interaction of CM with pharmacologic thrombolysis. In vitro
studies have shown CM-induced inhibition of clot dissolution
(14,15) and plasminogen activation (16). However, the mech-
anisms proposed are contradictory, one study suggesting that
the inhibitory effect is due to the electrical charge of CM
molecules (16), while another showed that iohexol (low-
osmolar, nonionic CM) and diatrizoate (high-osmolar, ionic
CM) but not ioxaglate (low-osmolar, ionic CM) delayed
alteplase-induced thrombolysis (15).
Administration of thrombolytic agents for acute myocardial
infarction has profound effects on hemostasis, activating both
lytic and prothrombotic mechanisms. Since CM may interact
with all factors involved in these reactions (i.e., platelets,
endothelial cells and coagulation and fibrinolytic proteins), it is
difficult to predict the result of CM administration at the time
of thrombolytic therapy from in vitro experiments. The aim of
our study was twofold: 1) to evaluate the interaction between
different CM and the process of coronary artery thrombolysis
and 2) to test the relative importance of biophysical properties
(osmolality, electrical charge) for their effects in vivo.
Methods
Coronary artery thrombosis. Mongrel dogs weighing 18 to
30 kg were sedated with 2.5 mg kg21 xylazin (Rompun, Bayer
AG, Leverkusen, Germany), anesthetized with sodium pento-
barbital (15 mg kg21 bolus and 0.1 mg kg21 min21 infusion;
Nembutal, Sanofi, France), intubated and artificially ventilated
(Mark 7A respirator, Bird Corporation, Palm Springs, CA,
USA). A left thoracotomy was performed in the fifth intercos-
tal space, and the heart was suspended in a pericardial cradle.
The left anterior descending (LAD) coronary artery was
dissected free distal to the first diagonal branch. An electro-
magnetic coronary flow probe (Skalar MDL1401, Skalar Med-
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ical BV, Delft, The Netherlands) was positioned around the
artery, distal to a silk snare. Coronary thrombosis was induced
by placing a 3- to 5-mm long copper coil over an intracoronary
wire into the LAD, as previously described (17). There were no
visible diagonal branches between the copper coil and the flow
probe. An occlusive thrombus was formed in 2 to 104 min
(mean 26 6 25 SD). The coronary thrombus was allowed to
grow for 90 min before initiation of thrombolysis with alteplase
(recombinant tissue plasminogen activator; Actilyse, Boehr-
inger Ingelheim GmbH, Ingelheim, Germany; 0.1 mg kg21
intravenous bolus followed by a continuous infusion of 0.01 mg
kg21 min21 for 30 min) and co-therapy with aspirin (5 mg kg21
of acetylsalicylic acid intravenous bolus; Aspegic, Synthe´labo,
France) and heparin (heparin naturium; Heparine Rorer,
Rhoˆne-Poulenc Rorer, Belgium; 100 IU kg21 bolus plus 25 IU
kg21 h21 infusion). Ventricular arrhythmias were treated with
lidocaine boluses (Xylocaine, Astra Pharmaceuticals, Brussels,
Belgium). The ventilation was adjusted to maintain the pH and
arterial blood gases within a physiologic range. Blood loss was
compensated with a saline infusion adjusted according to the
hematocrit. Body temperature was kept constant with a heat-
ing pad. All experiments conformed with the “Position of
American Heart Association on Research Animal Use” and
were conducted with the approval of the Ethics Committee of
the University of Leuven.
Contrast media. After 70 min of coronary artery occlusion,
the dogs were randomized to an intracoronary injection of one
of the following: placebo (normal saline solution); the low-
osmolar, ionic CM ioxaglate (Hexabrix 320, Laboratories
Guerbet, France); the low-osmolar, nonionic CM iohexol
(Omnipaque 350, Nycomed, Belgium); or the high-osmolar,
ionic CM amidotrizoate (Urographin 76%, Schering AG,
Germany). A 5F catheter was positioned in the proximal LAD
under fluoroscopic control; fluoroscopy was not used during
the intracoronary injections to maintain the blinding. A total
volume of 2 ml kg21 was injected over 15 min, divided in
multiple intracoronary boluses separated by periods of reflow.
This dose was selected based on an estimated use of 150 ml
CM (2 ml kg21 for a 75 kg patient) during catheterization. Five
minutes after the end of CM injection, the intracoronary
position of the catheter tip was verified by fluoroscopy, the
catheter was withdrawn and thrombolytic therapy was initi-
ated. CM or placebo were prepared in a separate laboratory
room according to computer-generated randomization lists.
All investigators remained blinded to the allocated treatment
throughout the experiment.
Venous blood samples. Venous blood samples were col-
lected on 4% citrate at baseline (sample 1), 70 min after
coronary occlusion (before the administration of contrast
media, sample 2), after 90 min of occlusion (sample 3), at the
end of the alteplase infusion (sample 4) and at the end of
experiment (sample 5). The samples were cooled on ice,
centrifuged and stored at 220°C for analysis of activated
partial thromboplastin time ([aPTT]; using Synthasil, ORTHO
Diagnostics, Raritan, New Jersey, USA) and fibrinogen ac-
cording to the Clauss method. Both assays were run on a KC10
coagulometer (Amelung, Germany) employing a mechanical
end point. We have also measured a2-antiplasmin with a
chromogenic assay (Chromogenix, Sweden) and circulating
thrombin-antithrombin III (TAT) complexes with enzyme-
linked immunosorbent assay (Behringwerke, Germany).
Data acquisition and analysis. The aortic pressure, lead II
electrocardiogram and coronary flow analog signals were dig-
itized online at 1.000 Hz channel21 and recorded on a PC with
a commercially available software package (Windaq, Dataq
Instruments, Akron, Ohio, USA). The software stores the
digital input of each channel together with the time reference
in binary format (i.e., the signal intensity at each sampling
point together with its time reference taken from the internal
clock of the computer) and displays it on a screen resembling
the millimetric paper. The advantage over classical paper
recording is that at playback, the operator can choose the
number of data-points that will be displayed between two
consecutive grids on the screen. Typically, we have first used a
low compression level (0.04 s of digital recording displayed on
1 mm of the screen, corresponding to the 25 mm s21 speed of
paper recorders). This level of data compression allowed the
best evaluation of the coronary flow pattern (phasic or not).
The occurrence of cyclic flows was easier to identify at higher
compression levels (1 to 5 min of digital recording displayed on
1 cm on the screen). Coronary zero flow was confirmed
whenever needed by occluding the coronary artery for a few
seconds with the proximal snare. We have performed qualita-
tive and quantitative analysis of the flow curve. The qualitative
analysis was focused on identification of events (reperfusion,
cyclic flow and reocclusion; Fig. 1). The definitions of events
and of the derived time indexes are given in Table 1. Another
blinded investigator performed a second reading of the flow
curves. The two readings agreed for event detection in 96% of
the situations.
By storing data in digital format, we were able to perform
computer-assisted quantitative analysis of the flow curve. We
have used the built-in peak-detection software for labeling
maximums and minimums of the coronary flow and aortic
pressures curves for each heartbeat. The results of the peak
detection were checked at the low compression level (0.04
s/mm) and manual corrections were performed when needed.
The mean coronary flow and aortic pressure were then com-
puted for every heart cycle. The peak coronary flow and the
area under the flow curve (AUC) during therapy were mea-
sured. The individual variability in coronary flow and aortic
pressure were minimized by baseline normalization.
Abbreviations and Acronyms
aPTT 5 activated partial thromboplastin time
CM 5 radiographic contrast media
LAD 5 left anterior descending coronary
artery
TAT 5 thrombin-antithrombin III complex
TIMI 5 Thrombolysis In Myocardial Infarction
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Statistical analysis. Statistical analysis was performed with
the SAS software, release 6.03 (18). The normal distribution
was tested with Shapiro–Wilk statistic and transformations
were performed when appropriate. The treatment effect on
time parameters was tested with one-way analysis of variance
(ANOVA) (overall effect) and Dunnett’s t test (pairwise
comparisons) for the normal distributions, and with the
Kruskal–Wallis test (overall effect) and the Wilcoxon rank-sum
test (pairwise comparisons) for nonnormal distributions. The
main effects of time, group and the interaction time 3 group
on hemostasis parameters were tested with ANOVA for
repeated measurements. A p value of less than 0.05 was
considered significant. The experiment had a power of 0.90 to
detect a difference of 40 min in the reperfusion times, and of
0.65 to detect a 30-min difference. All calculations were
performed with the SAS procedures UNIVARIATE,
ANOVA, GLM and NPAR1WAY (18). Values are expressed
as mean 6 SD.
Results
A total of 59 experiments were performed. Nineteen dogs
were excluded, eight before the randomization stage (death
due to ventricular fibrillation early after occlusion: six dogs;
problems with the coronary artery dissection: two dogs). The
other 11 exclusions were due to recanalization of the LAD
during the intracoronary injection of CM before initiation of
thrombolytic therapy (six dogs; ioxaglate: one; iohexol: four;
amidotrizoate: one), inadequate flow signal (four dogs; saline:
two; ioxaglate: one; amidotrizoate: one) and death due to
ventricular fibrillation during reperfusion (ioxaglate: one dog).
The randomization process continued until 40 dogs completed
the study protocol, giving a total of 10 dogs per group.
Coronary flow. The coronary artery patency is schemati-
cally represented in Figure 2. Thrombolytic therapy induced
sustained reperfusion in the following proportions: 10 of 10
Figure 1. Strip chart (maximum compression). Top curve 5 ECG lead
II; middle curve 5 aortic pressure; bottom curve 5 coronary flow. The
experimental setup comprised a 90-min occlusion period followed by
thrombolysis with recombinant tissue plasminogen activator, alteplase
(bolus and 30-min infusion) and co-therapy with aspirin (bolus) and
heparin (bolus and 2-h infusion). Contrast media (CM) or placebo
were administered intracoronary, starting 20 min before thrombolysis.
The events identified by strip chart analysis (occlusion, reperfusion,
peak hyperemic flow and cyclic flow) were used for the calculation of
time parameters.
Table 1. Definitions of Events and Derived Time Indexes
Events Definitions
(Re)Occlusion Disappearance of the phasic coronary flow
pattern for at least 30 s; mean flow #1
ml min21
Reperfusion Appearance of the phasic coronary flow
pattern for at least 30 s; mean flow .1
ml min21
Optimal reperfusion Period of stable coronary perfusion with
evident hyperemia at the beginning and
without cyclic flows
Cyclic flows Cyclic variations of the mean coronary
flow not explained by changes in the
aortic pressure and/or arrhythmia
Time indexes Definitions
Time to reperfusion Time elapsed from initiation of
thrombolytic therapy until the first
episode of reperfusion, whether or not
this was followed by sustained coronary
artery perfusion
Time to optimal reperfusion Time elapsed from initiation of
thrombolytic therapy until the peak
hyperemic flow
Total perfusion time Total time of coronary artery perfusion
during the 120 min of therapy
Optimal perfusion time Time interval between onset of optimal
perfusion and occurrence of the first
episode of cyclic flow or reocclusion
Figure 2. Schematic representation of the patency status of the LAD
coronary artery. Black squares 5 zero flow; striped squares 5 periods
with cyclic flows; open (white) squares 5 periods with optimal
coronary perfusion. The time-point at which the peak hyperemic flow
occurred (at the beginning of optimal reperfusion) is marked with an
X. r-tPA 5 recombinant tissue plasminogen activator, alteplase.
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(placebo), 8 of 10 (ioxaglate), 6 of 10 (iohexol) and 6 of 10
(amidotrizoate). Late reperfusion (i.e., after the end of alte-
plase infusion) occurred in six dogs (placebo: two; ioxaglate:
one; iohexol: one; amidotrizoate: two). At the end of the
experiment the proportions of open LADs were 5 of 10 for the
placebo, 5 of 10 for ioxaglate, 2 of 10 for iohexol and 2 of 10 for
amidotrizoate. Optimal perfusion was maintained until the end
of the experiment in only two dogs in the placebo group, and
in none in the CM groups. Although more open LADs were
observed in the placebo group than in the CM groups, these
differences were not statistically significant. However, the
effects of CM were evident on the time indexes (Table 2).
Administration of iohexol and amidotrizoate prior to initiation
of thrombolytic therapy resulted in a significant delay in the
mean time to optimal reperfusion. With ioxaglate the reperfu-
sion time was not significantly different from placebo (p 5
0.35) or from the other two CM (p 5 0.16 vs. iohexol, and p 5
0.19 vs. amidotrizoate). A similar result was observed for the
perfusion times, with dogs receiving iohexol and amidotrizoate
showing shorter periods of optimal coronary artery perfusion
(see Table 2). The optimal perfusion time after ioxaglate
administration was similar to placebo and significantly longer
than after both amidotrizoate and iohexol. All time indexes
showed a large variability, mainly due to dogs in which
reperfusion was not induced (ioxaglate: two; iohexol: four;
amidotrizoate: two). When we excluded these experiments
from the analysis, the deleterious effects of amidotrizoate on
alteplase-induced thrombolysis were still evident (time to
optimal reperfusion 52 6 45 min vs. 21 6 11 min for placebo,
p , 0.05; optimal perfusion time, 26 6 29 vs. 58 6 37 for
placebo, p 5 0.056), although of a lower magnitude. For
iohexol, the mean time to optimal reperfusion was significantly
longer than for placebo (32 6 18 min vs. 21 6 11 min, p ,
0.05); the optimal perfusion time, although shorter, was not
significantly different from placebo (p 5 0.19).
The results of the quantitative curve analysis are summa-
rized in Table 2. In the absence of significant differences
between groups with regard to pressure parameters, the area
under the flow curve and the peak coronary flow during
thrombolysis were significantly larger in the placebo group
than in the iohexol group. A borderline significant difference
was observed between placebo and amidotrizoate (p 5 0.053
for AUC and p 5 0.09 for the coronary peak flow); there were
no significant differences between placebo and ioxaglate. Pres-
sure decreased during thrombolysis to a similar extent in all
groups.
Hemostasis parameters. The plasma TAT complex levels,
the aPTTs and fibrinogen concentrations are given in Table 3.
No significant changes were observed in these parameters
during CM injection. However, a small but significant decrease
in a2-antiplasmin concentration was observed in dogs that
received CM, but not in those receiving placebo (significant
time 3 group interaction, p , 0.01). The sample taken at the
end of alteplase infusion showed a marked decrease in fibrin-
ogen and a2-antiplasmin levels, probably due to continuous
lysis in the vial, since blood samples were not collected on
aprotinin (19). There was also a prolongation of the aPTT in
all animals, no significant differences between groups being
observed. The prothrombotic state induced by the copper-coil
was neutralized by aspirin and heparin to a similar extent in all
groups, as shown by the return of the TAT complex concen-
tration to baseline values.
Discussion
Effects of CM administration on coronary thrombolysis.
This report represents the first study of the in vivo effects of
CM on pharmacologic thrombolysis. In designing the experi-
ment we tried to mimic the clinical situation of acute myocar-
dial infarction: occlusive coronary thrombosis aged for 90 min,
standard intravenous thrombolysis with alteplase, co-therapy
with aspirin and heparin. Various parameters were defined for
the evaluation of the interference between CM and thrombol-
ysis. The reperfusion times and the normalized peak coronary
Table 2. Time Indexes, Aortic Pressure and LAD Flow
Placebo Ioxaglate Iohexol Diatrizoate
p
Value
Time indexes (min)
Time to reperfusion 15 6 8 36 6 47 61 6 54 51 6 47 0.06
Time to optimal reperfusion 21 6 11 40 6 44 67 6 48* 65 6 49* 0.02
Total perfusion time 80 6 34 75 6 43 45 6 46 45 6 43 0.08
Optimal perfusion time 58 6 40 57 6 37 21 6 26*† 21 6 28*† 0.01
Aortic pressure (mm Hg)
Baseline 124 6 18 129 6 20 135 6 20 123 6 15 0.44
Start medication 103 6 22 119 6 16 107 6 22 109 6 23 0.33
Pressure decrease during therapy 29 6 21 27 6 21 36 6 16 24 6 19 0.52
LAD flow
Baseline (ml min21) 8.6 6 2.9 11.5 6 7.9 8.6 6 2.9 9.9 6 3.7 0.43
Peak flow during therapy (normalized values) 1.7 6 0.4 1.46 6 0.98 0.96 6 1.04* 1.13 6 0.15 0.11
AUC (normalized values) 69.6 6 27.8 84.6 6 63.7 41.6 6 48.2* 40.0 6 40.2‡ 0.09
*p , 0.05 vs. placebo; †p , 0.05 vs. ioxaglate; ‡p 5 0.053 vs. placebo. Data are mean 6 SD. AUC 5 area under the flow curve; LAD 5 left anterior descending
coronary artery.
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flow are a measure of the direct effects of CM on alteplase-
induced clot lysis. Reperfusion therapy however not only aims
at opening the occluded coronary arteries, but also at prevent-
ing reocclusion and, therefore, we have defined indexes for the
global effects of CM on the reperfusion process. The total
perfusion time and the optimal perfusion time are a measure
of both the quality of initial reperfusion (a smaller residual
thrombus will have less procoagulant activity) and the absence
of late reocclusion due to the prothrombotic effects.
All parameters analyzed showed an inhibition of alteplase-
induced thrombolysis by iohexol and amidotrizoate: optimal
reperfusion occurred 40 min later with these agents than after
placebo. This delay may be highly relevant in the context of
acute myocardial infarction since the only way to limit necrosis
and preserve cardiac function is to restore blood flow as early
as possible (20). Furthermore, also cyclic flows and reocclusion
occurred more often and earlier after these two CM than after
placebo, in spite of standard anticoagulant and antithrombotic
therapy. Indeed, the aPTT levels at the end of the experiment
were well above the 1.5 to 2-fold increase currently recom-
mended (21).
Relative importance of biophysical properties. In contrast
to other studies (16), our results show that the electrical charge
of the CM molecule alone cannot predict the magnitude of the
effects on in vivo coronary thrombolysis: for a similar osmola-
lity, the ionic agent ioxaglate was superior to the nonionic
agent iohexol. On the other hand, for a similar ionic charge,
the low-osmolar agent ioxaglate was superior to the high-
osmolar agent diatrizoate. The combinations low-osmolar non-
ionic (iohexol) and high-osmolar ionic (amidotrizoate) were
associated with similar inhibition of alteplase-induced throm-
bolysis. Therefore, we hypothesize that both the ionic charge
and osmotic properties are equally important for the inhibition
of pharmacologic thrombolysis. The combination associated
with the smallest effects seems to be of low osmolality and
electrically charged molecules. Our results are supported by
the findings of Dehmer et al. (15), who have shown that clots
formed at thrombin challenge in the presence of iohexol and
amidotrizoate are more resistant to alteplase than those
formed in the presence of ioxaglate.
Effects on hemostasis. Intracoronary administration of CM
did not induce changes in the aPTT or fibrinogen concentra-
tion. We consider that our findings are not in contradiction
with the large body of evidence for an anticoagulant effect of
CM. Indeed, the studies in which such effects were found have
used higher CM concentrations (5,10,11,22). Similarly to our
results, Manotti et al. (23) also could not find significant
prolongations of the aPTT in patients receiving intraarterial
CM. There were no significant differences between groups with
regard to the TAT concentrations. It is likely that the intense
prothrombotic state induced by the copper coil masked the
effects of CM on thrombin generation. After initiation of
antithrombotic and anticoagulant therapy, the TAT concentra-
tions returned to baseline in all groups.
Table 3. Hemostasis Parameters
Placebo Ioxaglate Iohexol Diatrizoate
Fibrinogen (g/liter)
Baseline 1.85 6 0.54 1.74 6 0.28 1.96 6 0.54 1.75 6 0.35
Start CM 1.90 6 0.59 1.77 6 0.39 1.89 6 0.62 1.66 6 0.43
Start r-tPA 1.82 6 0.60 1.48 6 0.61 1.70 6 0.58 1.55 6 0.32
End r-tPA 0.07 6 0.02* 0.06 6 0.01* 0.07 6 0.02* 0.06 6 0.02*
End of experiment 1.61 6 0.60 1.55 6 0.46 1.63 6 0.51 1.40 6 0.52
aPTT (s)
Baseline 15 6 1 15 6 1 15 6 1 16 6 1
Start CM 16 6 2 16 6 2 16 6 2 16 6 1
Start r-tPA 15 6 2 17 6 3 15 6 2 17 6 2
End r-tPA 371 6 19* 384 6 13* 376 6 12* 349 6 69*
End of experiment 78 6 103* 118 6 144* 44 6 18* 66 6 37*
TAT (mg/ml)
Baseline 5.1 6 3.8 6.9 6 3.9 6.3 6 6.9 5.9 6 4.1
Start CM 9.8 6 7.0* 10.6 6 8.8* 11.9 6 10.6* 13.2 6 11.9*
Start r-tPA 15.2 6 15.7* 21.0 6 21.7* 14.0 6 8.4* 12.7 6 10.2*
End r-tPA 8.7 6 7.6 12.1 6 16.9 7.5 6 2.6 7.0 6 2.2
End of experiment 7.3 6 10.8 7.9 6 8.9 11.1 6 11.3 4.8 6 1.4
a2-Antiplasmin (%)
Baseline 91.0 6 4.6 93.0 6 8.4 93.1 6 5.0 92.3 6 3.5
Start CM 90.5 6 4.3 91.4 6 9.5 87.2 6 9.3 88.7 6 5.4
Start r-tPA 88.5 6 4.5 84.2 6 11.0* 80.5 6 10.9* 80.6 6 6.0*
End r-tPA 0.0 6 0.0* 0.0 6 0.0* 0.0 6 0.0* 0.0 6 0.0*
End of experiment 56.0 6 22.2* 47.3 6 23.4* 52.1 6 19.4* 48.7 6 23.1*
*p , 0.05 vs. baseline. Data are mean 6 SD. aPTT 5 activated partial thromboplastin time; r-tPA 5 recombinant
tissue-type plasminogen activator, alteplase; TAT 5 thrombin-antithrombin complex concentrations.
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A different effect between CM and placebo was observed
with respect to a2-antiplasmin concentrations. Dogs receiving
CM showed a small but significant decrease of this coagulation
parameter during the intracoronary administration, in contrast
to the placebo group in which there was no significant change.
These changes probably reflect the weak stimulation of endog-
enous fibrinolysis by CM, an effect that was also observed in
other studies (12,13). The differences between groups disap-
peared once intense activation of fibrinolysis was induced by
alteplase administration, in spite of different effects on the
reperfusion delay. This dual effect of CM (i.e., stimulation of
endogenous fibrinolysis and inhibition of pharmacologic
thrombolysis) is difficult to explain. The stimulating effect is
known to be related to CM-induced release of endogenous
tissue plasminogen activator (12,13). As for the resistance to
lysis, Carr et al. (14) have suggested that CM-induced changes
in fibrin structure represent the responsible mechanism, the
clots formed in the presence of CM being composed of fibrin
strands with lower mass/length ratio and with lower binding
affinities for tissue plasminogen activator. Our experiments
show that thrombi formed and aged in the absence of CM also
become more resistant to thrombolysis after a short contact
with certain CM.
Clinical implications. There are several potential implica-
tions of the interference between CM and thrombolysis. The
clinical importance of coronary artery patency at the end of
reperfusion therapy has been well established (24,25). As a
consequence, most of the trials of thrombolytic therapy have
used coronary angiography at various time points, typically at
90 min after initiation of therapy (26–30), but sometimes also
at 30 and 60 min (29,30); the landmark Thrombolysis In
Myocardial Infarction (TIMI) Phase I trial (31) used angiog-
raphy also at baseline. The choice for one CM or another is
generally left to the local investigator. Our results show that
different CM inhibit in vivo thrombolysis to different extents.
Therefore, uniform selection of CM for clinical trials may
induce less bias in the results.
The importance of CM on the results of thrombolytic trials
is also highlighted in a recent report of the TIMI 4 trial. In
analyzing the angiographic results, Gibson et al. (32) found
that in the absence of intracoronary injections before the
90-min angiogram, TIMI grade 3 flow was achieved signifi-
cantly more often. In a meta-analysis of 61 trials of thrombo-
lytic therapy, Verheugt et al. (33) have shown that reocclusion
occurred more often in those trials that included a baseline
angiography. These clinical observations might be explained by
our findings.
Although restricted to a small number of selected patients,
intracoronary infusions of thrombolytic agents may be valuable
in the treatment of acute myocardial infarction, of periproce-
dural thrombosis in percutaneous transluminal coronary an-
gioplasty (PTCA) and of chronic total occlusions (34). Local
infusions of thrombolytic agents are also used in the therapy of
peripheral arterial thrombosis (35). These are other clinical
situations in which CM can exert inhibitory effects on throm-
bolysis. The interference may be more important since CM are
administered prior to initiation of therapy in these situations.
Indeed, thrombolytic agents seem to be less efficient in dissolv-
ing clots embolized into the coronaries during PTCA proce-
dures (36).
Study limitations. Our model of coronary thrombosis has
certain limitations. First, the clots formed within the copper
coil are relatively platelet-poor in comparison to arterial
thrombi (37). However, this model has been successfully used
for the evaluation of thrombolytic and/or adjunctive therapies
on ripe coronary thrombi (17,38,39). Second, the chest was
opened and the heart was exposed. We have chosen this
experimental setup because we had to measure the effect of
therapy on coronary artery patency without the use of coronary
angiography. The snare occlusions for zeroing may have influ-
enced our results, especially the quantitative flow analysis.
Finally, blood samples were collected from a peripheral vein
and not from the coronary sinus and, therefore, we may have
overlooked local effects of CM on hemostasis. The possible
effects of CM on platelet function were also not evaluated.
Conclusions. In this animal model, administration of the
low-osmolar nonionic agent iohexol and of the high-osmolar
ionic agent diatrizoate significantly impaired alteplase-induced
thrombolysis. The low-osmolar ionic agent ioxaglate was asso-
ciated with the smallest delay in reperfusion and was not
significantly different from placebo. Ioxaglate was superior to
both iohexol and diatrizoate with regard to the maintenance of
optimal coronary perfusion. Contrast media-inhibition of phar-
macologic thrombolysis seems to be related to both ionic and
osmolar properties. These effects should be considered in the
design of clinical trials that use angiography for the evaluation
of coronary artery patency and in patients receiving local
infusions of thrombolytic agents.
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